Abstracts

To request a copy of an abstract listed below, please use the Contact Us form.

Berenson, J.R., Boccia, R.V., Bashey A., Levine, A.M., Koc, O.N., Callahan, J.A., Mazar, A.P., Reich, S.D. (2006) "Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies" Blood (ASH Annual Meeting Abstracts) 108(11):2593.

Doñate, F., Juarez, J., Maunia, M., Burnett, M., Trapp, V., Fruehauf, J., and Mazar, A. (2006) “SOD1 inhibition by tetrathiomolybdate demonstrates differential sensitivity against melanoma cell lines in vitro and in vivo: a possible method for identifying patients most likely to benefit from the second generation tetrathiomolybdate, ATN-224.” Eur. J. Cancer Supplements 4: 126.

Doñate, F., Lowndes, S., Juarez, J., Manuia, M., Smith, E., Liu, N., Hayward, C., Batuman, O., Harris, A. and Mazar, A. (2006) “Translation of in vitro markers of the anti-angiogenic and anti-tumor activity of the SOD1 inhibitor ATN-224 to clinical trials .” Eur. J. Cancer Supplements 4: 43.

Lowndes, S.A., Adams, A., Timms, A., Middleton, M., Hayward, C., Reich, S.D., Mazar, A.P., Harris, A.L. (2006) "Phase I study of ATN-224 in patients (pts) with advanced solid tumours" Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement):2065

Juarez, J.C., Manuia, M.M., Betancourt, O., Mazar, A.P. and Donate, F. (2006). “The inhibition of CuZn superoxide dismutase (SOD1) by ATN-224, a second generation tetrathiomolybdate, interferes with multiple signaling pathways in tumor and endothelial cells in vitro.” Proc. AACR 47: 4687.

Campbell, R.A.,Gordon, M.S., Betancourt, O., Juarez, J., Donate, F., Mazar, A. and Berenson, J.R. (2006). “ATN-224, an orally available small molecule inhibitor of SOD1, inhibits multiple signaling pathways associated with myeloma progression and has antitumor activity in a murine model of refractory myeloma growth.” Proc. AACR 47: 4859.

Parry, G.C., Beck, I., Callahan, J.A. and Mazar, A.P. (2005) “Inhibition of uPA binding to uPAR by monoclonal antibodies prevents tumor cell migration in vitro and tumor growth in vivo.” Thromb. And Haemost. 93: A27.

Danese, S., Sans, M., Spencer, D., Beck, I., Doñate, F., Plunkett, M., Campbell, M., West, G.A., Redline, R., Gasbarrini, A., Mazar, A., de la Motte, C., Levine, A.D. and Fiocchi, C. (2005). "Starving the inflamed gut: Angiogenesis blockade as a novel therapeutic approach to experimental colitis." Gastroenterology 128 (4, supp. 2): 289.

Juarez, J.C., Betancourt, O., Pirie-Shepherd, S., Au, J.L.-S., Mazar, A.P. and Doñate, F. (2005) “Inhibition of CuZn superoxide dismutase (SOD1) in tumor cells by the copper binder tetrathiomolybdate (ATN-224) leads to apoptosis and cell death.” Proc. AACR 46: 1388 (Abstract #5897).

Callahan, J.A., Beck, I., Bauer, T.W., Ellis, L.M., Mazar, A.P. and Parry, G.C. (2005) “In vitro and in vivo characterization of a monoclonal antibody, ATN-658, targeting the uPA system.” Proc. AACR 46: 1454 (Abstract #6179).

Khalili, P., Plunkett, M., Beck, I., Arimura, J., Mazar, A. and Rabbani, S. (2004) "Regression of primary breast tumor and blockage of osteolytic skeletal metastasis by a non-RGD based integrin binding peptide (ATN-161) targeting α5β1 and αvβ3 in a xenograft model of breast cancer.: Proc. AACR 45: 4001.

Rabbani, S.A., Khalili, P. and Mazar, A.P. (2003) “A non-RGD based integrin binding peptide (ATN-161) that targets activated alpha-5 beta-1 and alpha-v beta-3 blocks the development of osteolytic skeletal metastases in a xenograft model of breast cancer.” Clin Cancer Res 9 (suppl.): 6181S.

Parry, G.C., Callahan, J.A., Truong, F., Tel-Tsur, Z., Plunkett, M.L. and Mazar, A.P. (2003) “Evaluation of monoclonal antibodies targeting the uPA system for internalization and delivery of cytotoxic agents.” Clin Cancer Res 9 (suppl.): 6195 Clin Cancer Res 9 (suppl.): 6181S S.

Plunkett, M.L., Beck, I., Avery, A.J., Tel-Tsur, Z., Yu, M., Livant, D., Arimura, J., Truong, F. and Mazar, A.P. (2003) “Combining low dose chemotherapy with low dose anti-angiogenic agents (ATN-161 and ATN-224) leads to increased anti-tumor activity in prostate cancer xenograft models.” Proc. Amer. Assoc. Cancer Res.: 3730.

Doñate, F., Guan, X., Callahan, J.A., Mazar, A.P. and Parry, G.C. (2003) “ATN-161 (Ac-PHSCN-NH2) has potent anti-angiogenic activity through multiple mechanisms of action and localizes to newly formed blood vessels in vivo.” Proc. Amer. Assoc. Cancer Res.: 63.

Hensley, H.H. and Mazar, A.P. (2003) “Evaluation of the anti-angiogenic agent ATN-161 by dynamic magnetic resonance imaging in a mouse model.” Proc. Amer. Assoc. Cancer Res.: 59.

Parry, G.C., Plunkett, M.L., Tarui, T., Takada, Y., Tel-Tsur, Z., Truong, F. and Mazar, A.P. (2002) "Development of monoclonal antibodies targeting the uPA system for diagnosis and therapy." Eur J Cancer 38 (suppl. 7): S151.

Plunkett, M.L., Parry, G.C., Tel-Tsur, Z., Bera, M., Beck, I., Avery, J., Callahan, J., Yin, J., Truong, F., Betancourt, O., Pirie-Shepherd, S., Stoeltzing, O., Livant, D., Ellis, L.M. and Mazar, A. (2002) "Dose and schedule optimization of a novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including a5b1 and avb3." Eur J Cancer 38 (suppl. 7): S82.

Doñate, F., Juarez, J.C., Guan, X., Hopkins, S.A., Yoon, W.Y., O’Hare, S.M., Gladstone, P.L., Price, M.L., Allan, A.K., Ternansky, R.J. and Mazar, A.P. (2002) "Minimization of the anti-angiogenic Histidine-Proline Rich Glycoprotein (HPRG) protein." Eur J Cancer 38 (suppl. 7): S79.

Plunkett, M.L., Tel-Tsur, Z., Bera, M., Beck, I., Avery, J., Livant, D. and Mazar, A. P. (2002) "A novel anti-angiogenic/anti-metastatic peptide, ATN-161 (Ac-PHSCN-NH2), which targets multiple fully activated integrins including a5b1 and avb3, leads to increased anti-tumor activity and increased survival in multiple tumor models when combined with chemotherapy." Eur J Cancer 38 (suppl. 7): S79.

Juarez, J.C., Shipulina, N.V., Guan, X., Plunkett, M.L.,  Parry, G.C.,  Zhang, J-C., McCrae, K.R., Mazar, A.P.,  Morgan, W.T.,  and Doñate, F. " The Histidine-Proline Rich Glycoprotein (HPRG) has potent anti-angiogenic and anti-tumor activities mediated through the Histidine-Proline (H/P) domain" Presented at American Association for Cancer Research 93rd Annual Meeting (April 2002), San Francisco, CA

Pirie-Shepherd, S., Lau, E., Callahan, J., and Mazar, A. " Differential Expression of IL-8 from endothelial cells treated with Tetrathiomolybdate and bFGF or VEGF" Presented at Keystone Conference on Angiogenesis (Feb 2002), Banff, Alberta, CANADA

Price, M.L.P., Guida, W. C., Jackson, T.E., Nydick, J.A., Gladstone, P.L. , Juarez, J.C. , Doñate, F., Ternansky, R.J. " Structure-based de novo design of novel N-(2,4-dioxo-1,2,3,4-tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors" Molecular Simulations in Structural Biology and Drug Discovery. San Francisco, CA (2002).

Stoeltzing, O., Liu, W., Reinmuth, N., Fan, F., Livant, D.L., Mazar, A.P., Ellis, L.M. (2001) "Reduction of colon cancer growth by a novel antiangiogenic agent that targets the integrin a5b1." Clin Cancer Res. 7(11, suppl.): 3656s.

Al-Atrash, G., Kitson, R.P., Xue, Y., Mazar, A.P., Kim, M.H., Goldfarb, R.H. (2001) "uPA and uPAR Contribute to NK Cell Invasion Through the Extracellular Matrix: Cooperation of uPA/uPAR and Matrix Metalloproteinases in NK Cell Invasion." Proc. Amer. Assoc. Cancer Res. 42: 5090.

Rabbani, S.A., Gladu, J. and Mazar, A.P. (2001) "Induction of c-fos Oncogene in Human Osteosarcoma Cells (SaOS2) by Urokinase (uPA) Via the Ras-Raf-MAPK Signaling Pathway" Proc. Amer. Assoc. Cancer Res. 42: 72.

Zhang, J-C, Juarez, J., Shaw, D.E., Mazar, A.P. and McCrae, K.R. (2000) "Peptides Derived from High Molecular Weight Kininogen (HK) Domains 3 and 5 Inhibit Endothelial Cell Proliferation and Induce Endothelial Cell Apoptosis" Proc. American Society for Hematology.

Al-Atrash, G., Kitson, R. P., Kim, M. H., Mazar, A. P. and Goldfarb, R. H. (2000) "Urokinase Plasminogen Activator and Its Receptor in NK Cells: Contribution to Extracellular Matrix Degradation and Impact on NK Cell Accumulation into Cancer Metastases." FASEB J 14 (supp. 6): A1024.